{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:09:32Z","timestamp":1788498572299,"version":"build-2803163510"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1-TR-002384"],"award-info":[{"award-number":["UL1-TR-002384"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Prostate cancer (PC) staging with conventional imaging often includes multiparametric magnetic resonance (MR) of the prostate, computed tomography (CT) of the chest, abdomen, and pelvis, and whole-body bone scintigraphy. The recent development of highly sensitive and specific prostate specific membrane antigen (PSMA) positron emission tomography (PET) has suggested that prior imaging techniques may be insufficiently sensitive or specific, particularly when evaluating small pathologic lesions. As PSMA PET\/CT is considered to be superior for multiple clinical indications, it is being deployed as the new multidisciplinary standard-of-care. Given this, we performed a cost-effectiveness analysis of [<jats:sup>18<\/jats:sup>F]DCFPyL PSMA PET\/CT imaging in the evaluation of PC relative to conventional imaging and anti-3-[<jats:sup>18<\/jats:sup>F]FACBC (<jats:sup>18<\/jats:sup>F-Fluciclovine) PET\/CT. We also conducted a single institution review of PSMA PET\/CT scans performed primarily for research indications from January 2018 to October 2021. Our snapshot of this period of time in our catchment demonstrated that PSMA PET\/CT imaging was disproportionately accessed by men of European ancestry (EA) and those residing in zip codes associated with a higher median household income. The cost-effectiveness analysis demonstrated that [<jats:sup>18<\/jats:sup>F]DCFPyL PET\/CT should be considered as an alternative to anti-3-[<jats:sup>18<\/jats:sup>F]FACBC PET\/CT and standard of care imaging for prostate cancer staging. [<jats:sup>18<\/jats:sup>F]DCFPyL PET\/CT is a new imaging modality to evaluate PC patients with higher sensitivity and specificity in detecting disease than other prostate specific imaging studies. Despite this, access may be inequitable. This discrepancy will need to be addressed proactively as the distribution network of the radiotracer includes both academic and non-academic sites nationwide.<\/jats:p>","DOI":"10.1038\/s41598-023-35567-w","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T10:02:36Z","timestamp":1684836156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Complex implementation factors demonstrated when evaluating cost-effectiveness and monitoring racial disparities associated with [18F]DCFPyL PET\/CT in prostate cancer men"],"prefix":"10.1038","volume":"13","author":[{"given":"Kritika","family":"Subramanian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juana","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Huicochea Castellanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Ivanidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu","family":"Nagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha","family":"Youn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jones T.","family":"Nauseef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"key":"35567_CR1","unstructured":"Key Statistics for Prostate Cancer | Prostate Cancer Facts. https:\/\/www.cancer.org\/cancer\/prostate-cancer\/about\/key-statistics.html (2020)."},{"key":"35567_CR2","unstructured":"Prostate Cancer-Statistics. Cancer.Net. https:\/\/www.cancer.net\/cancer-types\/prostate-cancer\/statistics (2012)."},{"key":"35567_CR3","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/cncr.32604","volume":"126","author":"SS Butler","year":"2020","unstructured":"Butler, S. S. et al. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012. Cancer 126, 717\u2013724 (2020).","journal-title":"Cancer"},{"key":"35567_CR4","unstructured":"Insurance Coverage of Prostate Cancer Screening. https:\/\/www.medicare.gov\/coverage\/prostate-cancer-screenings."},{"key":"35567_CR5","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1002\/cncr.33498","volume":"127","author":"DC Patel","year":"2021","unstructured":"Patel, D. C. et al. Cancer diagnoses and survival rise as 65-year-olds become Medicare-eligible. Cancer 127, 2302\u20132310 (2021).","journal-title":"Cancer"},{"key":"35567_CR6","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/JU.0000000000001385","volume":"205","author":"ME DeWitt-Foy","year":"2021","unstructured":"DeWitt-Foy, M. E., Gam, K., Modlin, C., Kim, S. P. & Abouassaly, R. Race, decisional regret and prostate cancer beliefs: Identifying targets to reduce racial disparities in prostate cancer. J. Urol. 205, 426\u2013433 (2021).","journal-title":"J. Urol."},{"key":"35567_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.44027","volume":"5","author":"K Yamoah","year":"2022","unstructured":"Yamoah, K. et al. Racial and ethnic disparities in prostate cancer outcomes in the Veterans affairs health care system. JAMA Netw. Open 5, e2144027 (2022).","journal-title":"JAMA Netw. Open"},{"key":"35567_CR8","first-page":"225","volume":"2","author":"S Vijayakumar","year":"1996","unstructured":"Vijayakumar, S., Weichselbaum, R., Vaida, F., Dale, W. & Hellman, S. Prostate-specific antigen levels in African\u2013Americans correlate with insurance status as an indicator of socioeconomic status. Cancer J. Sci. Am. 2, 225\u2013233 (1996).","journal-title":"Cancer J. Sci. Am."},{"key":"35567_CR9","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s00259-017-3852-8","volume":"45","author":"M Sathekge","year":"2018","unstructured":"Sathekge, M. et al. 68Ga-PSMA-11 PET\/CT in primary staging of prostate carcinoma: preliminary results on differences between black and white South-Africans. Eur. J. Nucl. Med. Mol. Imaging 45, 226\u2013234 (2018).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"35567_CR10","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1001\/jama.2020.17020","volume":"324","author":"R Deka","year":"2020","unstructured":"Deka, R. et al. Association between African American race and clinical outcomes in men treated for low-risk prostate cancer with active surveillance. JAMA 324, 1747\u20131754 (2020).","journal-title":"JAMA"},{"key":"35567_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.18318","volume":"3","author":"RB Parikh","year":"2020","unstructured":"Parikh, R. B. et al. Comparison by race of conservative management for low-risk and intermediate-risk prostate cancers in Veterans from 2004 to 2018. JAMA Netw. Open 3, e2018318 (2020).","journal-title":"JAMA Netw. Open"},{"key":"35567_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.1839","volume":"3","author":"SA Fletcher","year":"2020","unstructured":"Fletcher, S. A. et al. Geographic distribution of racial differences in prostate cancer mortality. JAMA Netw. Open 3, e201839 (2020).","journal-title":"JAMA Netw. Open"},{"key":"35567_CR13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.31349","volume":"3","author":"SL Washington","year":"2020","unstructured":"Washington, S. L. et al. Regional variation in active surveillance for low-risk prostate cancer in the US. JAMA Netw. Open 3, e2031349 (2020).","journal-title":"JAMA Netw. Open"},{"key":"35567_CR14","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/cncr.32666","volume":"126","author":"P Riviere","year":"2020","unstructured":"Riviere, P. et al. Survival of African American and non-Hispanic white men with prostate cancer in an equal-access health care system. Cancer 126, 1683\u20131690 (2020).","journal-title":"Cancer"},{"key":"35567_CR15","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/jamaoncol.2019.0826","volume":"5","author":"RT Dess","year":"2019","unstructured":"Dess, R. T. et al. Association of Black race with prostate cancer-specific and other-cause mortality. JAMA Oncol. 5, 975\u2013983 (2019).","journal-title":"JAMA Oncol."},{"key":"35567_CR16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1370\/afm.7","volume":"1","author":"RJ Volk","year":"2003","unstructured":"Volk, R. J., Spann, S. J., Cass, A. R. & Hawley, S. T. Patient education for informed decision making about prostate cancer screening: A randomized controlled trial with 1-year follow-up. Ann. Fam. Med. 1, 22\u201328 (2003).","journal-title":"Ann. Fam. Med."},{"key":"35567_CR17","first-page":"101","volume":"6","author":"SS Taneja","year":"2004","unstructured":"Taneja, S. S. Imaging in the diagnosis and management of prostate cancer. Rev. Urol. 6, 101\u2013113 (2004).","journal-title":"Rev. Urol."},{"key":"35567_CR18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ijrobp.2013.10.023","volume":"89","author":"AD Falchook","year":"2014","unstructured":"Falchook, A. D., Salloum, R. G., Hendrix, L. H. & Chen, R. C. Use of bone scan during initial prostate cancer workup, downstream procedures, and associated Medicare costs. Int. J. Radiat. Oncol. Biol. Phys. 89, 243\u2013248 (2014).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"35567_CR19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262412","author":"M Abghari-Gerst","year":"2021","unstructured":"Abghari-Gerst, M. et al. A comprehensive assessment of 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer: Results from a prospective multi-center study in 2005 patients. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. https:\/\/doi.org\/10.2967\/jnumed.121.262412 (2021).","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"35567_CR20","doi-asserted-by":"publisher","unstructured":"Rousseau, C., Le Thiec, M., Maucherat, B., Frindel, M. & Fleury, V. Place of molecular imaging in the management of prostate cancer. Cancer Radiother. J. Soc. Francaise Radiother. Oncol. https:\/\/doi.org\/10.1016\/j.canrad.2021.07.032 (2021).","DOI":"10.1016\/j.canrad.2021.07.032"},{"key":"35567_CR21","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s40273-022-01156-4","volume":"40","author":"R Song","year":"2022","unstructured":"Song, R., Jeet, V., Sharma, R., Hoyle, M. & Parkinson, B. Cost-effectiveness analysis of prostate-specific membrane antigen (PSMA) positron emission tomography\/computed tomography (PET\/CT) for the primary staging of prostate cancer in Australia. Pharmacoeconomics 40, 807\u2013821 (2022).","journal-title":"Pharmacoeconomics"},{"key":"35567_CR22","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13244-022-01265-w","volume":"13","author":"ECA van der Sar","year":"2022","unstructured":"van der Sar, E. C. A. et al. Cost-effectiveness of the implementation of [68Ga]Ga-PSMA-11 PET\/CT at initial prostate cancer staging. Insights Imaging 13, 132 (2022).","journal-title":"Insights Imaging"},{"key":"35567_CR23","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2967\/jnumed.120.251751","volume":"62","author":"MD Bucknor","year":"2021","unstructured":"Bucknor, M. D. et al. Disparities in PET imaging for prostate cancer at a tertiary academic medical center. J. Nucl. Med. 62, 695\u2013699 (2021).","journal-title":"J. Nucl. Med."},{"key":"35567_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05520-y","author":"DA Pattison","year":"2021","unstructured":"Pattison, D. A. et al. Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68 Ga]Ga-PSMA-11 PET\/CT imaging in patients with confirmed prostate cancer. Eur. J. Nucl. Med. Mol. Imaging https:\/\/doi.org\/10.1007\/s00259-021-05520-y (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"35567_CR25","unstructured":"Local Coverage Article for Billing and Coding: Radiopharmaceutical Agents (A55052). https:\/\/www.cms.gov\/medicare-coverage-database\/details\/article-details.aspx?articleId=55052."},{"key":"35567_CR26","unstructured":"CMS Grants Transitional Pass-Through Payment Status for PSMA PET Imaging Agent for Prostate Cancer-SNMMI. https:\/\/www.snmmi.org\/NewsPublications\/NewsDetail.aspx?ItemNumber=39211."},{"key":"35567_CR27","unstructured":"Article-Billing and Coding: Positron Emission Tomography Scans Coverage (A54666). https:\/\/www.cms.gov\/medicare-coverage-database\/view\/article.aspx?articleid=54666."},{"key":"35567_CR28","unstructured":"US Counties Database | Simplemaps.com. https:\/\/simplemaps.com\/data\/us-counties."},{"key":"35567_CR29","unstructured":"US Cities Database | Simplemaps.com. https:\/\/simplemaps.com\/data\/us-cities."},{"key":"35567_CR30","unstructured":"Kepler.gl. Accessed 14 February 2021. https:\/\/docs.kepler.gl\/docs\/user-guides (2020)."},{"key":"35567_CR31","unstructured":"NCCN Guidelines for Patients Early Stage Prostate Cancer. Vol. 80. Accessed 6 September 2021. https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/prostate-early-patient.pdf (2020)."},{"key":"35567_CR32","unstructured":"NCCN Guidelines for Patients Advanced Stage Prostate Cancer. Vol. 84. Accessed 6 September 2021. https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/prostate-advanced-patient.pdf (2020)."},{"key":"35567_CR33","unstructured":"Eaton, J. W. GNU Octave. https:\/\/www.gnu.org\/software\/octave\/about."},{"key":"35567_CR34","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s40273-018-0697-3","volume":"36","author":"AJ Hatswell","year":"2018","unstructured":"Hatswell, A. J., Bullement, A., Briggs, A., Paulden, M. & Stevenson, M. D. Probabilistic sensitivity analysis in cost-effectiveness models: Determining model convergence in cohort models. Pharmacoeconomics 36, 1421\u20131426 (2018).","journal-title":"Pharmacoeconomics"},{"key":"35567_CR35","unstructured":"Actuarial Life Table. https:\/\/www.ssa.gov\/oact\/STATS\/table4c6.html."},{"key":"35567_CR36","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1046\/j.1525-1497.1998.00211.x","volume":"13","author":"DK Owens","year":"1998","unstructured":"Owens, D. K. Interpretation of cost-effectiveness analyses. J. Gen. Intern. Med. 13, 716\u2013717 (1998).","journal-title":"J. Gen. Intern. Med."},{"key":"35567_CR37","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1001\/jama.2017.1704","volume":"317","author":"DA Barocas","year":"2017","unstructured":"Barocas, D. A. et al. Association between radiation therapy, surgery, or observation for localized prostate cancer and patient-reported outcomes after 3 years. JAMA 317, 1126\u20131140 (2017).","journal-title":"JAMA"},{"key":"35567_CR38","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1080\/14737140.2017.1374178","volume":"17","author":"R Ratta","year":"2017","unstructured":"Ratta, R., Grassi, P., Fuc\u00e0, G., Verzoni, E. & Procopio, G. Castration-naive metastatic prostate cancer: Reshaping old paradigms. Expert Rev. Anticancer Ther. 17, 879\u2013881 (2017).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"35567_CR39","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41391-020-00310-3","volume":"24","author":"F Saad","year":"2021","unstructured":"Saad, F., B\u00f6gemann, M., Suzuki, K. & Shore, N. Treatment of nonmetastatic castration-resistant prostate cancer: Focus on second-generation androgen receptor inhibitors. Prostate Cancer Prostatic Dis. 24, 323\u2013334 (2021).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"35567_CR40","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.urolonc.2018.09.005","volume":"36","author":"G Sun","year":"2018","unstructured":"Sun, G. et al. What kind of patients with castration-na\u00efve prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysis. Urol. Oncol. 36, 505\u2013517 (2018).","journal-title":"Urol. Oncol."},{"key":"35567_CR41","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.urology.2005.08.047","volume":"67","author":"PJ Rossi","year":"2006","unstructured":"Rossi, P. J., Clark, P. E., Papagikos, M. A., McCullough, D. L. & Lee, W. R. Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer. Urology 67, 349\u2013353 (2006).","journal-title":"Urology"},{"key":"35567_CR42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4103\/iju.IJU_355_18","volume":"35","author":"BZ McCormick","year":"2019","unstructured":"McCormick, B. Z., Mahmoud, A. M., Williams, S. B. & Davis, J. W. Biochemical recurrence after radical prostatectomy: Current status of its use as a treatment endpoint and early management strategies. Indian J. Urol. IJU J. Urol. Soc. India 35, 6\u201317 (2019).","journal-title":"Indian J. Urol. IJU J. Urol. Soc. India"},{"key":"35567_CR43","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/jama.294.4.433","volume":"294","author":"SJ Freedland","year":"2005","unstructured":"Freedland, S. J. et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294, 433 (2005).","journal-title":"JAMA"},{"key":"35567_CR44","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.urology.2006.03.075","volume":"68","author":"PA Kupelian","year":"2006","unstructured":"Kupelian, P. A., Mahadevan, A., Reddy, C. A., Reuther, A. M. & Klein, E. A. Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer. Urology 68, 593\u2013598 (2006).","journal-title":"Urology"},{"key":"35567_CR45","doi-asserted-by":"crossref","unstructured":"ASTRO definition of biochemical failure is outperformed by alternatives. Nat. Clin. Pract. Urol. 4, 121\u2013121 (2007).","DOI":"10.1038\/ncpuro0719"},{"key":"35567_CR46","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.2214\/AJR.19.21905","volume":"214","author":"P Bhargava","year":"2020","unstructured":"Bhargava, P., Ravizzini, G., Chapin, B. F. & Kundra, V. Imaging biochemical recurrence after prostatectomy: Where are we headed?. Am. J. Roentgenol. 214, 1248\u20131258 (2020).","journal-title":"Am. J. Roentgenol."},{"key":"35567_CR47","unstructured":"Search the Physician Fee Schedule | CMS. https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search."},{"key":"35567_CR48","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaoncol.2018.3701","volume":"5","author":"JG Trogdon","year":"2019","unstructured":"Trogdon, J. G., Falchook, A. D., Basak, R., Carpenter, W. R. & Chen, R. C. Total medicare costs associated with diagnosis and treatment of prostate cancer in elderly men. JAMA Oncol. 5, 60\u201366 (2019).","journal-title":"JAMA Oncol."},{"issue":"107","key":"35567_CR49","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejca.2018.11.024","volume":"1990","author":"S Nolte","year":"2019","unstructured":"Nolte, S. et al. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States. Eur. J. Cancer Oxf. Engl. 1990(107), 153\u2013163 (2019).","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"35567_CR50","doi-asserted-by":"crossref","unstructured":"Pickard, A. S. et al. United States valuation of EQ-5D-5L health states using an international protocol. Value Health J. Int. Soc. Pharmacoecon. Outcomes Res. 22, 931\u2013941 (2019).","DOI":"10.1016\/j.jval.2019.02.009"},{"key":"35567_CR51","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders, G. D. et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second panel on cost-effectiveness in health and medicine. JAMA 316, 1093\u20131103 (2016).","journal-title":"JAMA"},{"key":"35567_CR52","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/heapol\/czaa073","volume":"35","author":"M Haacker","year":"2020","unstructured":"Haacker, M., Hallett, T. B. & Atun, R. On discount rates for economic evaluations in global health. Health Policy Plan. 35, 107\u2013114 (2020).","journal-title":"Health Policy Plan."},{"key":"35567_CR53","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05261-y","author":"DA Ferraro","year":"2021","unstructured":"Ferraro, D. A. et al. Diagnostic performance of 68Ga-PSMA-11 PET\/MRI-guided biopsy in patients with suspected prostate cancer: A prospective single-center study. Eur. J. Nucl. Med. Mol. Imaging https:\/\/doi.org\/10.1007\/s00259-021-05261-y (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"35567_CR54","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1097\/JU.0000000000001095","volume":"204","author":"M Alemozaffar","year":"2020","unstructured":"Alemozaffar, M. et al. [18F]Fluciclovine positron emission tomography\/computerized tomography for preoperative staging in patients with intermediate to high risk primary prostate cancer. J. Urol. 204, 734\u2013740 (2020).","journal-title":"J. Urol."},{"key":"35567_CR55","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.euo.2020.08.012","volume":"5","author":"AT Lenis","year":"2020","unstructured":"Lenis, A. T. et al. Prostate-specific membrane antigen positron emission tomography\/computed tomography compared with conventional imaging for initial staging of treatment-na\u00efve intermediate- and high-risk prostate cancer: A retrospective single-center study. Eur. Urol. Oncol. 5, 544 (2020).","journal-title":"Eur. Urol. Oncol."},{"key":"35567_CR56","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","volume":"20","author":"J Calais","year":"2019","unstructured":"Calais, J. et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: A prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 20, 1286\u20131294 (2019).","journal-title":"Lancet Oncol."},{"key":"35567_CR57","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262821","author":"J Ferdinandus","year":"2021","unstructured":"Ferdinandus, J. et al. PSMA PET validates higher rates of metastatic disease for European Association of Urology Biochemical Recurrence Risk Groups: An international multicenter study. J. Nucl. Med. https:\/\/doi.org\/10.2967\/jnumed.121.262821 (2021).","journal-title":"J. Nucl. Med."},{"key":"35567_CR58","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ajur.2020.02.001","volume":"8","author":"Y Yuminaga","year":"2021","unstructured":"Yuminaga, Y. et al. 68Ga-PSMA PET\/CT versus CT and bone scan for investigation of PSA failure post radical prostatectomy. Asian J. Urol. 8, 170\u2013175 (2021).","journal-title":"Asian J. Urol."},{"key":"35567_CR59","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1007\/s00259-021-05415-y","volume":"48","author":"A Salavati","year":"2021","unstructured":"Salavati, A. et al. A bicentric retrospective analysis of clinical utility of 18F-fluciclovine PET in biochemically recurrent prostate cancer following primary radiation therapy: Is it helpful in patients with a PSA rise less than the Phoenix criteria?. Eur. J. Nucl. Med. Mol. Imaging 48, 4463\u20134471 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"35567_CR60","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13550-020-00618-0","volume":"10","author":"HD Zacho","year":"2020","unstructured":"Zacho, H. D. et al. Added value of 68Ga-PSMA PET\/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous 99mTc bone scintigraphy. EJNMMI Res. 10, 31 (2020).","journal-title":"EJNMMI Res."},{"key":"35567_CR61","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1200\/JCO.2010.30.2075","volume":"29","author":"SK Bechis","year":"2011","unstructured":"Bechis, S. K., Carroll, P. R. & Cooperberg, M. R. Impact of age at diagnosis on prostate cancer treatment and survival. J. Clin. Oncol. 29, 235\u2013241 (2011).","journal-title":"J. Clin. Oncol."},{"key":"35567_CR62","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00520-017-3953-8","volume":"26","author":"M Cuypers","year":"2018","unstructured":"Cuypers, M. et al. The impact of prostate cancer diagnosis and treatment decision-making on health-related quality of life before treatment onset. Support. Care Cancer 26, 1297\u20131304 (2018).","journal-title":"Support. Care Cancer"},{"key":"35567_CR63","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1186\/s12885-020-07244-y","volume":"20","author":"N Hou\u00e9d\u00e9","year":"2020","unstructured":"Hou\u00e9d\u00e9, N. et al. Impact on quality of life 3 years after diagnosis of prostate cancer patients below 75 at diagnosis: An observational case\u2013control study. BMC Cancer 20, 757 (2020).","journal-title":"BMC Cancer"},{"key":"35567_CR64","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.6004\/jnccn.2020.0053","volume":"18","author":"SM Horwitz","year":"2020","unstructured":"Horwitz, S. M. et al. NCCN guidelines insights: T-cell lymphomas, version 1.2021: Featured updates to the NCCN guidelines. J. Natl. Comprehens. Cancer Netw. 18, 1460\u20131467 (2020).","journal-title":"J. Natl. Comprehens. Cancer Netw."},{"key":"35567_CR65","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","volume":"11","author":"M Bolla","year":"2010","unstructured":"Bolla, M. et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 11, 1066\u20131073 (2010).","journal-title":"Lancet Oncol."},{"key":"35567_CR66","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/pros.23317","volume":"77","author":"MD van Die","year":"2017","unstructured":"van Die, M. D. et al. A placebo-controlled double-blinded randomized pilot study of combination phytotherapy in biochemically recurrent prostate cancer. Prostate 77, 765\u2013775 (2017).","journal-title":"Prostate"},{"key":"35567_CR67","first-page":"472","volume":"24","author":"JW Robinson","year":"2006","unstructured":"Robinson, J. W. et al. Quality of life 2 years after salvage cryosurgery for the treatment of local recurrence of prostate cancer after radiotherapy. Urol. Oncol. Semin. Orig. Investig. 24, 472\u2013486 (2006).","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"35567_CR68","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00728","author":"HL Rush","year":"2021","unstructured":"Rush, H. L. et al. Quality of life in men with prostate cancer randomly allocated to receive docetaxel or abiraterone in the STAMPEDE trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.21.00728 (2021).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"35567_CR69","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","volume":"30","author":"NW Clarke","year":"2019","unstructured":"Clarke, N. W. et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: Long-term survival results from the STAMPEDE trial. Ann. Oncol. 30, 1992\u20132003 (2019).","journal-title":"Ann. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35567-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35567-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35567-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T19:24:15Z","timestamp":1702495455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35567-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["35567"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-35567-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,23]]},"assertion":[{"value":"10 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this Article was revised: In the original version of this Article, the author name Sandra Huicochea Castellanos was incorrectly indexed. The original Article has been corrected.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8321"}}